Axonal transport is the process whereby motor proteins actively navigate microtubules to deliver diverse cargoes, such as organelles, from one end of the axon to the other, and is widely regarded as essential for nerve development, function and survival. Mutations in genes encoding key components of the transport machinery, including motor proteins, motor adaptors and microtubules, have been discovered to cause neurological disease. Moreover, disruptions in axonal cargo trafficking have been extensively reported across a wide range of nervous system disorders. However, whether these impairments have a major causative role in, are contributing to or are simply a consequence of neuronal degeneration remains unclear. Therefore, the fundamental relevance of defective trafficking along axons to nerve dysfunction and pathology is often debated. In this article, we review the latest evidence emerging from human and in vivo studies on whether perturbations in axonal transport are indeed integral to the pathogenesis of neurological disease.
Mutations in various genes encoding components of the axonal transport machinery have been implicated in the pathogenesis of neurological diseases.
Defective axonal trafficking has been linked to many nervous system disorders, but whether it is a cause or consequence of neuropathology remains largely unresolved.
Intravital imaging of transport in axons of live mice provides some of the most compelling evidence that trafficking disturbances contribute to neuronal dysfunction.
Targeting of specific mechanisms of axonal transport might be a valid therapeutic strategy to treat neurological disease.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hirokawa, N. & Tanaka, Y. Kinesin superfamily proteins (KIFs): various functions and their relevance for important phenomena in life and diseases. Exp. Cell Res. 334, 16–25 (2015).
Terenzio, M., Schiavo, G. & Fainzilber, M. Compartmentalized signaling in neurons: from cell biology to neuroscience. Neuron 96, 667–679 (2017).
Reck-Peterson, S. L., Redwine, W. B., Vale, R. D. & Carter, A. P. The cytoplasmic dynein transport machinery and its many cargoes. Nat. Rev. Mol. Cell Biol. 19, 382–398 (2018).
Villarroel-Campos, D., Schiavo, G. & Lazo, O. M. The many disguises of the signalling endosome. FEBS Lett. 592, 3615–3632 (2018).
Maday, S. Mechanisms of neuronal homeostasis: autophagy in the axon. Brain Res. 1649, 143–150 (2016).
Ferguson, S. M. Axonal transport and maturation of lysosomes. Curr. Opin. Neurobiol. 51, 45–51 (2018).
Rishal, I. & Fainzilber, M. Axon–soma communication in neuronal injury. Nat. Rev. Neurosci. 15, 32–42 (2014).
Gibbs, K. L., Greensmith, L. & Schiavo, G. Regulation of axonal transport by protein kinases. Trends Biochem. Sci. 40, 597–610 (2015).
Brady, S. T. & Morfini, G. A. Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases. Neurobiol. Dis. 105, 273–282 (2017).
Dubey, J., Ratnakaran, N. & Koushika, S. P. Neurodegeneration and microtubule dynamics: death by a thousand cuts. Front. Cell. Neurosci. 9, 343 (2015).
Barlan, K. & Gelfand, V. I. Microtubule-based transport and the distribution, tethering, and organization of organelles. Cold Spring Harb. Perspect. Biol. 9, a025817 (2017).
Hirokawa, N., Niwa, S. & Tanaka, Y. Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron 68, 610–638 (2010).
Hinckelmann, M.-V., Zala, D. & Saudou, F. Releasing the brake: restoring fast axonal transport in neurodegenerative disorders. Trends Cell Biol. 23, 634–643 (2013).
Maday, S., Twelvetrees, A. E., Moughamian, A. J. & Holzbaur, E. L. F. Axonal transport: cargo-specific mechanisms of motility and regulation. Neuron 84, 292–309 (2014).
Neefjes, J. & van der Kant, R. Stuck in traffic: an emerging theme in diseases of the nervous system. Trends Neurosci. 37, 66–76 (2014).
DiMauro, S., Schon, E. A., Carelli, V. & Hirano, M. The clinical maze of mitochondrial neurology. Nat. Rev. Neurol. 9, 429–444 (2013).
Millecamps, S. & Julien, J.-P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 14, 161–176 (2013).
Prior, R., Van Helleputte, L., Benoy, V. & Van Den Bosch, L. Defective axonal transport: a common pathological mechanism in inherited and acquired peripheral neuropathies. Neurobiol. Dis. 105, 300–320 (2017).
Milde, S., Adalbert, R., Elaman, M. H. & Coleman, M. P. Axonal transport declines with age in two distinct phases separated by a period of relative stability. Neurobiol. Aging 36, 971–981 (2015).
Vagnoni, A., Hoffmann, P. C. & Bullock, S. L. Reducing Lissencephaly-1 levels augments mitochondrial transport and has a protective effect in adult Drosophila neurons. J. Cell Sci. 129, 178–190 (2016).
Sleigh, J. N. & Schiavo, G. Older but not slower: aging does not alter axonal transport dynamics of signalling endosomes in vivo. Matters https://doi.org/10.19185/matters.201605000018 (2016).
Brouhard, G. J. & Rice, L. M. Microtubule dynamics: an interplay of biochemistry and mechanics. Nat. Rev. Mol. Cell Biol. 19, 451–463 (2018).
Rao, A. N. & Baas, P. W. Polarity sorting of microtubules in the axon. Trends Neurosci. 41, 77–88 (2018).
Baas, P. W., Rao, R. N., Matamoros, A. J. & Leo, L. Stability properties of neuronal microtubules. Cytoskeleton 73, 442–460 (2016).
Miki, H., Setou, M., Kaneshiro, K. & Hirokawa, N. All kinesin superfamily protein, KIF, genes in mouse and human. Proc. Natl Acad. Sci. USA 98, 7004–7011 (2001).
Carter, A. P., Diamant, A. G. & Urnavicius, L. How dynein and dynactin transport cargos: a structural perspective. Curr. Opin. Struct. Biol. 37, 62–70 (2016).
Zhang, K. et al. Cryo-EM reveals how human cytoplasmic dynein is auto-inhibited and activated. Cell 169, 1303–1314 (2017).
McKenney, R. J., Huynh, W., Tanenbaum, M. E., Bhabha, G. & Vale, R. D. Activation of cytoplasmic dynein motility by dynactin–cargo adapter complexes. Science 345, 337–341 (2014).
Schlager, M. A. et al. Bicaudal D family adaptor proteins control the velocity of Dynein-based movements. Cell Rep. 8, 1248–1256 (2014).
Budzinska, M., Wicher, K. B. & Terenzio, M. Neuronal roles of the bicaudal D family of motor adaptors. Vitam. Horm. 104, 133–152 (2017).
DeSantis, M. E. et al. Lis1 has two opposing modes of regulating cytoplasmic dynein. Cell 170, 1197–1208 (2017).
Huang, J., Roberts, A. J., Leschziner, A. E. & Reck-Peterson, S. L. Lis1 acts as a “clutch” between the ATPase and microtubule-binding domains of the dynein motor. Cell 150, 975–986 (2012).
Baumbach, J. et al. Lissencephaly-1 is a context-dependent regulator of the human dynein complex. eLife 6, e21768 (2017).
Yi, J. Y. et al. High-resolution imaging reveals indirect coordination of opposite motors and a role for LIS1 in high-load axonal transport. J. Cell Biol. 195, 193–201 (2011).
Zyłkiewicz, E. et al. The N-terminal coiled-coil of Ndel1 is a regulated scaffold that recruits LIS1 to dynein. J. Cell Biol. 192, 433–445 (2011).
Olenick, M. A. & Holbaur, E. L. F. Dynein activators and adaptors at a glance. J. Cell Sci. 132, jcs227132 (2019).
Griffin, J. W., Price, D. L., Drachman, D. B. & Engel, W. K. Axonal transport to and from the motor nerve ending. Ann. N. Y. Acad. Sci. 274, 31–45 (1976).
Roy, S. Seeing the unseen: the hidden world of slow axonal transport. Neuroscientist 20, 71–81 (2014).
Brown, A., Wang, L. & Jung, P. Stochastic simulation of neurofilament transport in axons: the “stop-and-go” hypothesis. Mol. Biol. Cell 16, 4243–4255 (2005).
Garner, J. A. & Mahler, H. R. Biogenesis of presynaptic terminal proteins. J. Neurochem. 49, 905–915 (1987).
Twelvetrees, A. E. et al. The dynamic localization of cytoplasmic dynein in neurons is driven by kinesin-1. Neuron 90, 1000–1015 (2016).
Allen, R. D., Metuzals, J., Tasaki, I., Brady, S. T. & Gilbert, S. P. Fast axonal transport in squid giant axon. Science 218, 1127–1129 (1982).
Brady, S. T., Lasek, R. J. & Allen, R. D. Fast axonal transport in extruded axoplasm from squid giant axon. Science 218, 1129–1131 (1982).
Klinman, E. & Holzbaur, E. L. F. Walking forward with kinesin. Trends Neurosci. 41, 555–556 (2018).
Schiavo, G., Greensmith, L., Hafezparast, M. & Fisher, E. M. C. Cytoplasmic dynein heavy chain: the servant of many masters. Trends Neurosci. 36, 641–651 (2013).
Poirier, K. et al. Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly. Nat. Genet. 45, 639–647 (2013).
Tsai, J.-W., Lian, W.-N., Kemal, S., Kriegstein, A. R. & Vallee, R. B. Kinesin 3 and cytoplasmic dynein mediate interkinetic nuclear migration in neural stem cells. Nat. Neurosci. 13, 1463–1471 (2010).
Doobin, D. J., Kemal, S., Dantas, T. J. & Vallee, R. B. Severe NDE1-mediated microcephaly results from neural progenitor cell cycle arrests at multiple specific stages. Nat. Commun. 7, 12551 (2016).
Hu, D. J.-K. et al. Dynein recruitment to nuclear pores activates apical nuclear migration and mitotic entry in brain progenitor cells. Cell 154, 1300–1313 (2013).
Tsai, J.-W., Bremner, K. H. & Vallee, R. B. Dual subcellular roles for LIS1 and dynein in radial neuronal migration in live brain tissue. Nat. Neurosci. 10, 970–979 (2007).
Ori-McKenney, K. M. & Vallee, R. B. Neuronal migration defects in the Loa dynein mutant mouse. Neural Dev. 6, 26 (2011).
Poirier, K. et al. Mutations in the neuronal β-tubulin subunit TUBB3 result in malformation of cortical development and neuronal migration defects. Hum. Mol. Genet. 19, 4462–4473 (2010).
Jaglin, X. H. et al. Mutations in the β-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat. Genet. 41, 746–752 (2009).
Yamada, K. et al. Heterozygous mutations of the kinesin KIF21A in congenital fibrosis of the extraocular muscles type 1 (CFEOM1). Nat. Genet. 35, 318–321 (2003).
Cheng, L. et al. Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82, 334–349 (2014).
Scoto, M. et al. Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophy. Neurol. 84, 668–679 (2015).
Rossor, A. M. et al. Phenotypic and molecular insights into spinal muscular atrophy due to mutations in BICD2. Brain 138, 293–310 (2015).
Huynh, W. & Vale, R. D. Disease-associated mutations in human BICD2 hyperactivate motility of dynein–dynactin. J. Cell Biol. 216, 3051–3060 (2017).
Hoang, H. T., Schlager, M. A., Carter, A. P. & Bullock, S. L. DYNC1H1 mutations associated with neurological diseases compromise processivity of dynein–dynactin–cargo adaptor complexes. Proc. Natl Acad. Sci. USA 114, E1597–E1606 (2017).
Chen, X.-J. et al. Proprioceptive sensory neuropathy in mice with a mutation in the cytoplasmic Dynein heavy chain 1 gene. J. Neurosci. 27, 14515–14524 (2007).
Hafezparast, M. et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300, 808–812 (2003).
Bilsland, L. G. et al. Deficits in axonal transport precede ALS symptoms in vivo. Proc. Natl Acad. Sci. USA 107, 20523–20528 (2010).
Zhao, J. et al. Dync1h1 mutation causes proprioceptive sensory neuron loss and impaired retrograde axonal transport of dorsal root ganglion neurons. CNS Neurosci. Ther. 22, 593–601 (2016).
Hwang, S. H. et al. Distal hereditary motor neuropathy type 7B with Dynactin 1 mutation. Mol. Med. Rep. 14, 3362–3368 (2016).
Farrer, M. J. et al. DCTN1 mutations in Perry syndrome. Nat. Genet. 41, 163–165 (2009).
Puls, I. et al. Mutant dynactin in motor neuron disease. Nat. Genet. 33, 455–456 (2003).
Mishima, T. et al. Perry syndrome: a distinctive type of TDP-43 proteinopathy. J. Neuropathol. Exp. Neurol. 76, 676–682 (2017).
Lloyd, T. E. et al. The p150Glued CAP-Gly domain regulates initiation of retrograde transport at synaptic termini. Neuron 74, 344–360 (2012).
Chevalier-Larsen, E. S., Wallace, K. E., Pennise, C. R. & Holzbaur, E. L. F. Lysosomal proliferation and distal degeneration in motor neurons expressing the G59S mutation in the p150Glued subunit of dynactin. Hum. Mol. Genet. 17, 1946–1955 (2008).
Moughamian, A. J. & Holzbaur, E. L. F. Dynactin is required for transport initiation from the distal axon. Neuron 74, 331–343 (2012).
Weedon, M. N. et al. Exome sequencing identifies a dync1h1 mutation in a large pedigree with dominant axonal Charcot–Marie–Tooth disease. Am. J. Hum. Genet. 89, 308–312 (2011).
Rivière, J.-B. et al. KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am. J. Hum. Genet. 89, 219–230 (2011).
Lee, J.-R. et al. De novo mutations in the motor domain of KIF1A cause cognitive impairment, spastic paraparesis, axonal neuropathy, and cerebellar atrophy. Hum. Mutat. 36, 69–78 (2015).
Tanaka, Y. et al. The molecular motor KIF1A transports the TrkA neurotrophin receptor and is essential for sensory neuron survival and function. Neuron 90, 1215–1229 (2016).
Chiba, K. et al. Disease-associated mutations hyperactivate KIF1A motility and anterograde axonal transport of synaptic vesicle precursors. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.1905690116 (2019).
Reid, E. et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet. 71, 1189–1194 (2002).
Füger, P. et al. Spastic paraplegia mutation N256S in the neuronal microtubule motor KIF5A disrupts axonal transport in a Drosophila HSP model. PLOS Genet. 8, e1003066 (2012).
Brenner, D. et al. Hot-spot KIF5A mutations cause familial ALS. Brain 141, 688–697 (2018).
Nicolas, A. et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97, 1268–1283 (2018).
Zhao, C. et al. Charcot–Marie–Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bβ. Cell 105, 587–597 (2001).
Martin, M. et al. Cytoplasmic dynein, the dynactin complex, and kinesin are interdependent and essential for fast axonal transport. Mol. Biol. Cell 10, 3717–3728 (1999).
LaMonte, B. H. et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 34, 715–727 (2002).
Stokin, G. B. et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science 307, 1282–1288 (2005).
De Vos, K. J. & Hafezparast, M. Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiol. Dis. 105, 283–299 (2017).
Toyoshima, I. et al. Kinesin and cytoplasmic dynein in spinal spheroids with motor neuron disease. J. Neurol. Sci. 159, 38–44 (1998).
Galvin, J. E., Uryu, K., Lee, V. M. & Trojanowski, J. Q. Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein. Proc. Natl Acad. Sci. USA 96, 13450–13455 (1999).
Fanara, P. et al. Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J. Clin. Invest. 122, 3159–3169 (2012).
Hares, K. et al. Overexpression of kinesin superfamily motor proteins in Alzheimer’s disease. J. Alzheimers Dis. 60, 1511–1524 (2017).
Pantelidou, M. et al. Differential expression of molecular motors in the motor cortex of sporadic ALS. Neurobiol. Dis. 26, 577–589 (2007).
Hares, K. et al. Axonal motor protein KIF5A and associated cargo deficits in multiple sclerosis lesional and normal-appearing white matter. Neuropathol. Appl. Neurobiol. 43, 227–241 (2017).
Chu, Y. et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease. Brain 135, 2058–2073 (2012).
Cash, A. D. et al. Microtubule reduction in Alzheimer’s disease and aging is independent of tau filament formation. Am. J. Pathol. 162, 1623–1627 (2003).
Zhang, F. et al. Posttranslational modifications of α-tubulin in Alzheimer disease. Transl. Neurodegener. 4, 9 (2015).
Ren, Y. et al. Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons. Stem Cells 33, 68–78 (2015).
Cartelli, D. et al. Parkin absence accelerates microtubule aging in dopaminergic neurons. Neurobiol. Aging 61, 66–74 (2018).
Brunden, K. R., Lee, V. M.-Y., Smith, A. B., Trojanowski, J. Q. & Ballatore, C. Altered microtubule dynamics in neurodegenerative disease: therapeutic potential of microtubule-stabilizing drugs. Neurobiol. Dis. 105, 328–335 (2017).
Saporta, M. A. et al. Axonal Charcot–Marie–Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp. Neurol. 263, 190–199 (2015).
Xu, C.-C., Denton, K. R., Wang, Z.-B., Zhang, X. & Li, X.-J. Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy. Dis. Model. Mech. 9, 39–49 (2016).
Sleigh, J. N., Vagnoni, A., Twelvetrees, A. E. & Schiavo, G. Methodological advances in imaging intravital axonal transport. F1000Res. 6, 200 (2017).
Guo, W. et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 8, 861 (2017).
Plucińska, G. & Misgeld, T. Imaging of neuronal mitochondria in situ. Curr. Opin. Neurobiol. 39, 152–163 (2016).
Hinckelmann, M.-V. et al. Self-propelling vesicles define glycolysis as the minimal energy machinery for neuronal transport. Nat. Commun. 7, 13233 (2016).
Alami, N. H. et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536–543 (2014).
Baldwin, K. R., Godena, V. K., Hewitt, V. L. & Whitworth, A. J. Axonal transport defects are a common phenotype in Drosophila models of ALS. Hum. Mol. Genet. 25, 2378–2392 (2016).
Lacovich, V. et al. Tau isoforms imbalance impairs the axonal transport of the amyloid precursor protein in human neurons. J. Neurosci. 37, 58–69 (2017).
Moutaux, E. et al. Neuronal network maturation differently affects secretory vesicles and mitochondria transport in axons. Sci. Rep. 8, 13429 (2018).
Pal, A. et al. High content organelle trafficking enables disease state profiling as powerful tool for disease modelling. Sci. Data 5, 180241 (2018).
Berry, B. J., Smith, A. S. T., Young, J. E. & Mack, D. L. Advances and current challenges associated with the use of human induced pluripotent stem cells in modeling neurodegenerative disease. Cells Tissues Organs 205, 331–349 (2018).
Drouin-Ouellet, J., Pircs, K., Barker, R. A., Jakobsson, J. & Parmar, M. Direct neuronal reprogramming for disease modeling studies using patient-derived neurons: what have we learned? Front. Neurosci. 11, 530 (2017).
Gibbs, K. L., Kalmar, B., Sleigh, J. N., Greensmith, L. & Schiavo, G. In vivo imaging of axonal transport in murine motor and sensory neurons. J. Neurosci. Methods 257, 26–33 (2016).
Lewis, T. L., Turi, G. F., Kwon, S.-K., Losonczy, A. & Polleux, F. Progressive decrease of mitochondrial motility during maturation of cortical axons in vitro and in vivo. Curr. Biol. 26, 2602–2608 (2016).
Smit-Rigter, L. et al. Mitochondrial dynamics in visual cortex are limited in vivo and not affected by axonal structural plasticity. Curr. Biol. 26, 2609–2616 (2016).
Knabbe, J., Nassal, J. P., Verhage, M. & Kuner, T. Secretory vesicle trafficking in awake and anaesthetized mice: differential speeds in axons versus synapses. J. Physiol. 596, 3759–3773 (2018).
Mitchell, D. J. et al. Trk activation of the ERK1/2 kinase pathway stimulates intermediate chain phosphorylation and recruits cytoplasmic dynein to signaling endosomes for retrograde axonal transport. J. Neurosci. 32, 15495–15510 (2012).
Pathak, A. et al. Retrograde degenerative signaling mediated by the p75 neurotrophin receptor requires p150Glued deacetylation by axonal HDAC1. Dev. Cell 46, 376–387 (2018).
Kiryu-Seo, S., Ohno, N., Kidd, G. J., Komuro, H. & Trapp, B. D. Demyelination increases axonal stationary mitochondrial size and the speed of axonal mitochondrial transport. J. Neurosci. 30, 6658–6666 (2010).
Badal, K. K. et al. Synapse formation activates a transcriptional program for persistent enhancement in the bi-directional transport of mitochondria. Cell Rep. 26, 507–517 (2019).
Smith, S. E. & Bonni, A. in The Molecular and Cellular Basis of Neurodegenerative Diseases (ed. Wolfe, M. S.) 415–440 (Elsevier, 2018).
Sajic, M. et al. Impulse conduction increases mitochondrial transport in adult mammalian peripheral nerves in vivo. PLOS Biol. 11, e1001754 (2013).
Wang, T. et al. Flux of signalling endosomes undergoing axonal retrograde transport is encoded by presynaptic activity and TrkB. Nat. Commun. 7, 12976 (2016).
Shidara, Y. & Hollenbeck, P. J. Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a Drosophila model of Friedreich ataxia. J. Neurosci. 30, 11369–11378 (2010).
Devireddy, S., Liu, A., Lampe, T. & Hollenbeck, P. J. The organization of mitochondrial quality control and life cycle in the nervous system in vivo in the absence of PINK1. J. Neurosci. 35, 9391–9401 (2015).
Godena, V. K. et al. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat. Commun. 5, 5245 (2014).
Fatouros, C. et al. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum. Mol. Genet. 21, 3587–3603 (2012).
Butler, V. J. et al. Tau/MAPT disease-associated variant A152T alters tau function and toxicity via impaired retrograde axonal transport. Hum. Mol. Genet. 28, 1498–1514 (2019).
Bergamin, G., Cieri, D., Vazza, G., Argenton, F. & Mostacciuolo, M. L. Zebrafish Tg(hb9:MTS-Kaede): a new in vivo tool for studying the axonal movement of mitochondria. Biochim. Biophys. Acta 1860, 1247–1255 (2016).
Dukes, A. A. et al. Live imaging of mitochondrial dynamics in CNS dopaminergic neurons in vivo demonstrates early reversal of mitochondrial transport following MPP+ exposure. Neurobiol. Dis. 95, 238–249 (2016).
Bothwell, M. Recent advances in understanding neurotrophin signaling. F1000Res. 5, 1885 (2016).
Zhang, B., Tu, P., Abtahian, F., Trojanowski, J. Q. & Lee, V. M. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J. Cell Biol. 139, 1307–1315 (1997).
Williamson, T. L. & Cleveland, D. W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 2, 50–56 (1999).
Magrané, J., Cortez, C., Gan, W.-B. & Manfredi, G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 23, 1413–1424 (2014).
Gordon, D. et al. Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. Neurobiol. Dis. 121, 148–162 (2019).
Sleigh, J. N. et al. ALS mice carrying pathological mutant TDP-43, but not mutant FUS, display axonal transport defects in vivo. BioRxiv https://doi.org/10.1101/438812 (2018).
Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 3, 17071 (2017).
Devoy, A. et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in “FUSDelta14” knockin mice. Brain 140, 2797–2805 (2017).
Marinkovic, P. et al. Axonal transport deficits and degeneration can evolve independently in mouse models of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 109, 4296–4301 (2012).
Malik, B. et al. Absence of disturbed axonal transport in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 20, 1776–1786 (2011).
Sorbara, C. D. et al. Pervasive axonal transport deficits in multiple sclerosis models. Neuron 84, 1183–1190 (2014).
Morfini, G. et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat. Neurosci. 9, 907–916 (2006).
Halievski, K., Kemp, M. Q., Breedlove, S. M., Miller, K. E. & Jordan, C. L. Non-cell-autonomous regulation of retrograde motoneuronal axonal transport in an SBMA mouse model. eNeuro 3, e0062–16.2016 (2016).
Wang, W. et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum. Mol. Genet. 22, 4706–4719 (2013).
Morfini, G. A. et al. Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLOS ONE 8, e65235 (2013).
Moller, A., Bauer, C. S., Cohen, R. N., Webster, C. P. & De Vos, K. J. Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Hum. Mol. Genet. 26, 4668–4679 (2017).
Gibbs, K. L. et al. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 9, 596 (2018).
Ruschel, J. et al. Systemic administration of epothilone B promotes axon regeneration after spinal cord injury. Science 348, 347–352 (2015).
Mar, F. M., Bonni, A. & Sousa, M. M. Cell intrinsic control of axon regeneration. EMBO Rep. 15, 254–263 (2014).
Clark, A. J. et al. Epothilone D accelerates disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 44, 590–605 (2018).
Reed, N. A. et al. Microtubule acetylation promotes kinesin-1 binding and transport. Curr. Biol. 16, 2166–2172 (2006).
Dompierre, J. P. et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation. J. Neurosci. 27, 3571–3583 (2007).
d’Ydewalle, C. et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot–Marie–Tooth disease. Nat. Med. 17, 968–974 (2011).
Mo, Z. et al. Aberrant GlyRS–HDAC6 interaction linked to axonal transport deficits in Charcot–Marie–Tooth neuropathy. Nat. Commun. 9, 1007 (2018).
Taes, I. et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum. Mol. Genet. 22, 1783–1790 (2013).
Kalinski, A. L. et al. Deacetylation of Miro1 by HDAC6 blocks mitochondrial transport and mediates axon growth inhibition. J. Cell Biol. 218, 1871–1890 (2019).
Zhang, K. et al. Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J. Neurosci. 33, 7451–7462 (2013).
Cioni, J.-M. et al. Late endosomes act as mRNA translation platforms and sustain mitochondria in axons. Cell 176, 56–72 (2019).
Zhu, Y. B. & Sheng, Z. H. Increased axonal mitochondrial mobility does not slow amyotrophic lateral sclerosis (ALS)-like disease in mutant SOD1 mice. J. Biol. Chem. 286, 23432–23440 (2011).
Perlson, E. et al. A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration. J. Neurosci. 29, 9903–9917 (2009).
Fu, M. & Holzbaur, E. L. F. JIP1 regulates the directionality of APP axonal transport by coordinating kinesin and dynein motors. J. Cell Biol. 202, 495–508 (2013).
Lee, S., Pant, H. C. & Shea, T. B. Divergent and convergent roles for kinases and phosphatases in neurofilament dynamics. J. Cell Sci. 127, 4064–4077 (2014).
Stevenson, A. et al. Riluzole protects against glutamate-induced slowing of neurofilament axonal transport. Neurosci. Lett. 454, 161–164 (2009).
Tortarolo, M. et al. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol. Cell. Neurosci. 23, 180–192 (2003).
Ackerley, S. et al. p38α stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 26, 354–364 (2004).
Dewil, M., dela Cruz, V. F., van den Bosch, L. & Robberecht, W. Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1G93A-induced motor neuron death. Neurobiol. Dis. 26, 332–341 (2007).
Chico, L. K., Van Eldik, L. J. & Watterson, D. M. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov. 8, 892–909 (2009).
Hetman, M. & Gozdz, A. Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur. J. Biochem. 271, 2050–2055 (2004).
Hur, E.-M. & Zhou, F.-Q. GSK3 signalling in neural development. Nat. Rev. Neurosci. 11, 539–551 (2010).
Coffey, E. T. Nuclear and cytosolic JNK signalling in neurons. Nat. Rev. Neurosci. 15, 285–299 (2014).
Ally, S., Larson, A. G., Barlan, K., Rice, S. E. & Gelfand, V. I. Opposite-polarity motors activate one another to trigger cargo transport in live cells. J. Cell Biol. 187, 1071–1082 (2009).
Schuster, M. et al. Kinesin-3 and dynein cooperate in long-range retrograde endosome motility along a nonuniform microtubule array. Mol. Biol. Cell 22, 3645–3657 (2011).
Wu, C., Watts, M. E. & Rubin, L. L. MAP4K4 activation mediates motor neuron degeneration in amyotrophic lateral sclerosis. Cell Rep. 26, 1143–1156 (2019).
Xie, Y. et al. Endolysosomal deficits augment mitochondria pathology in spinal motor neurons of asymptomatic fALS mice. Neuron 87, 355–370 (2015).
The authors’ work is supported by the Medical Research Council Career Development Award (MR/S006990/1 to J.N.S.), a Wellcome Trust Postdoctoral Fellowship for Clinicians (110043/Z/15/Z to A.M.R.), a Wellcome Trust Senior Investigator Award (107116/Z/15/Z to G.S.), the European Union’s Horizon 2020 Research and Innovation programme under grant agreement 739572 (to G.S.) and a UK Dementia Research Institute Foundation award (to G.S.).
The authors declare no competing interests.
Peer review information
Nature Reviews Neurology thanks K. De Vos and other anonymous reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Online Mendelian Inheritance in Man: http://www.omim.org/
The ability of motor–cargo complexes to undergo axonal transport without dissociation from microtubules.
- Coiled-coil domains
A structural motif composed of two or more α-helices wrapped around each other to form a supercoil. The coiled-coil domain of the cytoplasmic dynein–dynactin complex connects the ATPase domain with the microtubule-binding domain.
- Run length
The total displacement covered by a motor–cargo complex without pausing.
- Microtubule gliding assays
An experimental technique that is used to assess the activity of motor proteins, in which microtubules and ATP are applied to motors bound to glass coverslips.
(ENU). A potent mutagen that is often used to generate mutant animal models.
Membranous organelles involved in intracellular transport, sorting and delivery of various substances, including growth factors, internalized from the cell exterior.
About this article
Cite this article
Sleigh, J.N., Rossor, A.M., Fellows, A.D. et al. Axonal transport and neurological disease. Nat Rev Neurol 15, 691–703 (2019). https://doi.org/10.1038/s41582-019-0257-2
Frontiers for Young Minds (2020)
Frontiers in Microbiology (2020)
Trends in Neurosciences (2020)
International Journal of Molecular Sciences (2020)